{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T06:25:30Z","timestamp":1724480730654},"reference-count":72,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2205,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Cardiol"],"DOI":"10.1002\/clc.4960281305","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T12:14:49Z","timestamp":1278504889000},"page":"19-27","source":"Crossref","is-referenced-by-count":6,"special_numbering":"supplement S1","title":["Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy"],"prefix":"10.1002","volume":"28","author":[{"given":"Jonathan","family":"Sackner-Bernstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,18]]},"reference":[{"key":"10.1002\/clc.4960281305-BIB1|cit1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","article-title":"ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB2|cit2","unstructured":"National Heart, Lung and Blood Institute http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3full.pdf 2005"},{"key":"10.1002\/clc.4960281305-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960281305-BIB4|cit4","unstructured":"American Heart Association http:\/\/www.americanheart.org\/downloadable\/heart\/1040391091015HDS_Stats_03.pdf 2003"},{"key":"10.1002\/clc.4960281305-BIB5|cit5","volume-title":"True Odds: How Risk Affects Your Everyday Life.","author":"Walsh","year":"1996"},{"key":"10.1002\/clc.4960281305-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group","volume":"336","author":"Appel","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.280.23.2001","article-title":"Intensive lifestyle changes for reversal of coronary heart disease","volume":"280","author":"Ornish","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960281305-BIB9|cit9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJM199302253280804","article-title":"The association of changes in physical-activity level and other lifestyle characteristics with mortality among men","volume":"328","author":"Paffenbarger","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB10|cit10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM200007063430103","article-title":"Primary prevention of coronary heart disease in women through diet and lifestyle","volume":"343","author":"Stampfer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM198405033101801","article-title":"Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death","volume":"310","author":"Davies","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB12|cit12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","article-title":"Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the assessment of treatment with lisinopril and survival (ATLAS) trial","volume":"102","author":"Uretsky","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/01.CIR.80.6.1675","article-title":"Diverse mechanisms of unexpected cardiac arrest in advanced heart failure","volume":"80","author":"Luu","year":"1989","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.CIR.93.7.1354","article-title":"Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death","volume":"93","author":"Farb","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB15|cit15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0735-6757(98)90128-0","article-title":"Gender differences in reported symptoms for acute myocardial infarction: Impact on pre-hospital delay time interval","volume":"16","author":"Meischke","year":"1998","journal-title":"Am J Emerg Med"},{"key":"10.1002\/clc.4960281305-BIB16|cit16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00063110-199912000-00007","article-title":"Is there a gender difference in aetiology of chest pain and symptoms associated with acute myocardial infarction?","volume":"6","author":"Herlitz","year":"1999","journal-title":"Eur J Emerg Med"},{"key":"10.1002\/clc.4960281305-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/01.CIR.47.6.1174","article-title":"Left ventricular size after acute myocardial infarction. Serial changes and their prognostic significance","volume":"47","author":"Kostuk","year":"1973","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB18|cit18","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1054\/jcaf.2002.129289","article-title":"Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction","volume":"8","author":"Udelson","year":"2002","journal-title":"J Card Fail"},{"key":"10.1002\/clc.4960281305-BIB19|cit19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/01.CIR.96.1.116","article-title":"End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators","volume":"96","author":"Migrino","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB20|cit20","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1161\/01.CIR.96.10.3294","article-title":"Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long-term use of captopril: Information from the Survival and Ventricular Enlargement (SAVE) trial","volume":"96","author":"St John Sutton","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB21|cit21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB24|cit24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"The Beta-Blocker Evaluation of Survival Trial Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB26|cit26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(94)90080-9","article-title":"Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture","volume":"106","author":"Fennessy","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1002\/clc.4960281305-BIB27|cit27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB28|cit28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB29|cit29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB30|cit30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0735-1097(83)80316-7","article-title":"A placebo-controlled trial of captopril in refractory chronic congestive heart failure","volume":"2","author":"Captopril Multicenter Research Group","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960281305-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB32|cit32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB33|cit33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB34|cit34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","article-title":"Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"327","author":"Swedberg","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB37|cit37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB38|cit38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB39|cit39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB41|cit41","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","article-title":"Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone","volume":"109","author":"Keidar","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/clc.4960281305-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960281305-BIB45|cit45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11883-005-0073-6","article-title":"Pleiotropic effects of statins: Moving beyond cholesterol control","volume":"7","author":"Garcia","year":"2005","journal-title":"Curr Atheroscler Rep"},{"key":"10.1002\/clc.4960281305-BIB46|cit46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB48|cit48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB49|cit49","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease; The Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"The Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB50|cit50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB54|cit54","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960281305-BIB55|cit55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"10.1002\/clc.4960281305-BIB55.2|cit56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1071-9164(98)90244-5","volume":"4","year":"1998","journal-title":"J Card Fail"},{"key":"10.1002\/clc.4960281305-BIB56|cit57","doi-asserted-by":"crossref","first-page":"13503","DOI":"10.1074\/jbc.M411859200","article-title":"Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts","volume":"280","author":"Madonna","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1002\/clc.4960281305-BIB57|cit58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0021-9150(73)90109-3","article-title":"The effects of propranolol on cholesterol-induced atheromatous lesions","volume":"18","author":"Whittington-Coleman","year":"1973","journal-title":"Atherosclerosis"},{"key":"10.1002\/clc.4960281305-BIB58|cit59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/01.RES.56.5.755","article-title":"Effects of propranolol on atherogenesis in the cholesterol-fed rabbit","volume":"56","author":"Chobanian","year":"1985","journal-title":"Circ Res"},{"key":"10.1002\/clc.4960281305-BIB59|cit60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-2999(95)00596-X","article-title":"Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation","volume":"294","author":"Yue","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/clc.4960281305-BIB60|cit61","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","author":"Beta-blocker Heart Attack Trial Research Group","year":"1982","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960281305-BIB61|cit62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"The Norwegian Multicenter Study Group","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB62|cit63","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1","volume":"2","author":"First International Study of Infarct Survival Collaborative Group","year":"1986","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB63|cit64","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial","volume":"2","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB64|cit65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","article-title":"First International Study of Infarct Survival Collaborative Group: Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial","volume":"6","author":"The MIAMI Trial Research Group","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960281305-BIB65|cit66","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/oxfordjournals.eurheartj.a062170","article-title":"The Lopressor Intervention Trial: Multicentre study of metoprolol in survivors of acute myocardial infarction","volume":"8","author":"Lopressor Intervention Trial Research Group","year":"1987","journal-title":"Eur Heart J"},{"key":"10.1002\/clc.4960281305-BIB66|cit67","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB67|cit68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB68|cit69","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB69|cit70","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/clc.4960281305-BIB70|cit71","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960281305-BIB71|cit72","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: Unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960281305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/clc.4960281305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T22:41:13Z","timestamp":1625179273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960281305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,18]]},"references-count":72,"journal-issue":{"issue":"S1"},"URL":"https:\/\/doi.org\/10.1002\/clc.4960281305","relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,18]]}}}